Omalizumab for the treatment of chronic urticaria

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria. The 2013 revision and update. Allergy 2014;69:868-87
   PubMed Web of Science ®Google Scholar
• Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis. Immunol Allergy Clin North Am 2014;34:33-52
   PubMedGoogle Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:869-73
   PubMed Web of Science ®Google Scholar
• Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality-of-life in Korean patients. Ann Dermatol 2009;21:226-9
   PubMedGoogle Scholar
• Silvares MR, Fortes MR, Miot HA. Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil). Rev Assoc Med Bras 2011;57:577-82
   PubMedGoogle Scholar
• Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9:169-80
   PubMed Web of Science ®Google Scholar
• Delong LK, Culler SD, Saini SS, et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008;144:35-9
   PubMedGoogle Scholar
• Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133:1270-7
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2014;69:e1-29
   PubMed Web of Science ®Google Scholar
• Weller K, Schoepke N, Krause K, et al. Selected urticaria patients benefit from a referral to tertiary care centres–results of an expert survey. J Eur Acad Dermatol Venereol 2013;27:e8-e16
   Google Scholar
• Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig 2006;26:1-11
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review. Allergy 2014;69:1275-9
   PubMed Web of Science ®Google Scholar
• Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419-28
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Nakonechna A, et al. The first international study assessing the economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: ASSURE-CSU. Allergy 2014;69(S99):111-99; Poster 244
   Google Scholar
• Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-8
   PubMed Web of Science ®Google Scholar
• Commins S, Platt-Mills T. Management of Anaphylaxis: Relevance of Causes and Future Trends in Treatment. In: Castells MC, Editor Anaphylaxis and Hypersensitivity Reactions. Humana Press; New York: 2011. pp. 345-54
   Google Scholar
• Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2014. [Epub ahead of print]
   Google Scholar
• Shields RL, Werther WR, Zioncheck K, et al. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int Arch Allergy Immunol 1995;107:412-3
   PubMed Web of Science ®Google Scholar
• Boushey HAJr. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001;108:S77-83
   PubMed Web of Science ®Google Scholar
• Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006;117:1415-8
   PubMed Web of Science ®Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3
   PubMed Web of Science ®Google Scholar
• Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:247-9
   PubMed Web of Science ®Google Scholar
• Güzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:1563-5
   PubMed Web of Science ®Google Scholar
• Asero R, Casalone R, Iemoli E. Extraordinary response to omalizumab in a child with severe chronic urticaria. Eur Ann Allergy Clin Immunol 2014;46:41-2
   PubMedGoogle Scholar
• Leiva-Salinas M, Frances L, Marin-Cabanas I, et al. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J Eur Acad Dermatol Venereol 2014. [Epub ahead of print]
   Google Scholar
• Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126:665-6
   PubMed Web of Science ®Google Scholar
• Gober LM, Sterba PM, Eckman JA, Saini S. Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients (abstract). J Allergy Clin Immunol 2008;121(Suppl 1):S147
   Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic urticaria/chronic spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomised placebo-controlled study. J Invest Dermatol 2014. [Epub ahead of print]
   Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Xolair (omalizumab) 150 mg solution for injection. UK Summary of Product Characteristics. Updated February. 2014. electronic Medicines Compendium Available from: www.medicines.org.uk/emc/medicine/24912 [Last accessed 21 March 2014]
   Google Scholar
• Tan RA, Corren J. Safety of omalizumab in asthma. Expert Opin Drug Saf 2011;10:463-71
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139:28-35
   PubMed Web of Science ®Google Scholar
• Novartis. Xolair® (omalizumab). Periodic Safety Update Report 18 (PSUR 18). December 2013
   Google Scholar
• Novartis Pharmaceuticals Corporation and Genentech Inc. Xolair (omalizumab): Prescribing Information. Updated July 2010 www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf [Last accessed 13 January 2014]
   Google Scholar
• Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010;65:1494-5
   PubMedGoogle Scholar
• Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154:177-80
   PubMed Web of Science ®Google Scholar
• Vieira Dos SR, Locks BB, Rabello de SJ, Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol 2014;170:469-71
   PubMedGoogle Scholar
• Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther 2013;13:1225-8
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014;73:57-62
   PubMed Web of Science ®Google Scholar
• Sussman G, Hebert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014;112:170-4
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Cold Urticaria Treatment With Xolair (CUTEX). A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU). Last updated 11 June 2014. [Last accessed 08 Aug 2014] Available from: http://clinicaltrials.gov/ct2/show/NCT01580592?term=CUTEX&rank=1
   Google Scholar
• Clinicaltrials.gov. Urticaria Facticia Treatment With Omalizumab (UFO). Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment. Last accessed 18 Jun 2014 Available from: http://clinicaltrials.gov/ct2/show/NCT02169115?term=UFO&rank=1 [last accessed 08 Aug 2014]
   Google Scholar
• Clinicaltrials.gov. Efficacy Study of Omalizumab in Cholinergic Urticaria (CUN-OMAL-UCOL). Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticaria. Last updated 18 Jan 2014. [Last accessed 08 Aug 2014] Available from: http://clinicaltrials.gov/ct2/show/NCT02012387?term=cun-omal-ucol&rank=1
   Google Scholar
• FDA; Novartis. and. Genentech. Xolair regulatory history and labelling from drugs@FDA. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 11 Aug 2014]
   Google Scholar
• Novartis and Genentech. Public summary document for omalizumab. Updated 19 March 2010. Available from: www.health.gov.au/internet/main/publishing.nsf/Content/C27A743EB81388A6CA257BF0001E004D/$File/Omalizumab%20112009.pdf [Last accessed 11 August 2014]
   Google Scholar
• Novartis Pharmaceuticals Canada Inc. Xolair product monograph. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=74602&lang=eng
   Google Scholar
• Asero R, Tedeschi A, Cugno M. Treatment of refractory chronic urticaria: current and future therapeutic options. Am J Clin Dermatol 2013;14:481-8
   PubMed Web of Science ®Google Scholar